Concepedia

Begoña de las Heras

BD

14

Publications

2.5K

Citations

12

H-Index

1997

Active since

Affiliations

Hospital Universitario La Paz(Current)

HistoGeneX (Belgium)

Covance (United States)

Eisai (United Kingdom)

Eisai (United States)

Begoña de las Heras is an author at Hospital Universitario La Paz specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

1997–2022

14

Publications

14

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2K citations · Full text

Effect of the COVID-19 pandemic on cancer treatment and research

Kamal S. Saini, Begoña de las Heras, Javier de Castro et al. · The Lancet Haematology · 2020 · 159 citations · Full text

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Richard D. Baird, Jos Kitzen, Paul A. Clarke et al. · Molecular Cancer Therapeutics · 2009 · 46 citations · Full text

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Kamal S. Saini, Carlo Lanza, Marco Romano et al. · British Journal of Cancer · 2020 · 46 citations · Full text

A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup>I-refractory differentiated thyroid cancer (SELECT).

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · Journal of Clinical Oncology · 2014 · 41 citations

, , +16

Rows per page

1–5 of 14